Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
February 07 2025 - 6:54AM
UK Regulatory
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members,
executives and associated persons
Trading in Novo Nordisk shares by board members,
executives and associated persons
Bagsværd, Denmark, 7 February 2025 — This
company announcement discloses the data of the transaction(s) made
in Novo Nordisk shares by the company’s board members, executives
and their associated persons in accordance with Article 19 of
Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated
persons have reported the transactions to Novo Nordisk and have
given Novo Nordisk power of attorney on their behalf to publish
trading in Novo Nordisk shares by the company’s board members,
executives and their associated persons.
Please find below a statement of such trading in shares issued
by Novo Nordisk.
|
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Marcus Schindler |
|
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Executive Vice President |
|
|
b) |
Initial notification/Amendment |
Initial notification |
|
|
3 |
Details of the issuer |
|
|
a) |
Name |
Novo Nordisk A/S |
|
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
|
4 |
Details of the transaction(s) |
|
|
a) |
Description of the financial instrument,
type of instrument, |
Shares
|
|
|
|
Identification code |
Novo Nordisk B DK0062498333 |
|
|
b) |
Nature of the transaction |
Sale of shares |
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
DKK 620.26 |
40,000 shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
40,000 shares
DKK 24,810,329 |
|
|
e) |
Date of the transaction |
2025-02-06 |
|
|
f) |
Place of the transaction |
Nasdaq Copenhagen |
|
Novo Nordisk is a leading global healthcare company, founded
in 1923 and headquartered in Denmark. Our purpose is to drive
change to defeat serious chronic diseases, built upon our heritage
in diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 72,000 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com,
Facebook, Instagram,
X, LinkedIn and
YouTube.
Contacts for further information
Media:
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com
Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com
Investors:
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com
Sina Meyer
+45 3079 6656
azey@novonordisk.com
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com
Max Ung
+45 3077 6414
mxun@novonordisk.com
Frederik Taylor Pitter
+1 609 613 0568
fptr@novonordisk.com
Company Announcement No 9 / 2025
Novo Nordisk (TG:NOV)
Historical Stock Chart
From Jan 2025 to Feb 2025
Novo Nordisk (TG:NOV)
Historical Stock Chart
From Feb 2024 to Feb 2025
